Clinical Trials Directory

Trials / Completed

CompletedNCT04386148

Impact of Obsidian ® ASG on Anastomotic Healing

Impact of Obsidian® ASG Autologous Platelet-rich Fibrin Matrix on Anastomotic Healing in Colorectal Surgery

Status
Completed
Phase
Study type
Observational
Enrollment
270 (actual)
Sponsor
Kepler University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The use of regenerative medicine in colorectal surgery constitutes an entirely new therapeutic principle. The aim of this new therapeutic approach is to reduce the anastomotic leak rate and minimise morbidity and mortality. The literature identifies the leak rate for colorectal operations as 3-39%.

Detailed description

Introduction: The use of regenerative medicine in colorectal surgery constitutes an entirely new therapeutic principle. The aim of this new therapeutic approach is to reduce the anastomotic leak rate and minimise morbidity and mortality. The literature identifies the leak rate for colorectal operations as 3-39%. Methods: This is a prospective, multi-centre descriptive study commencing in June 2018. As part of the elective laparoscopic colorectal surgery, an autologous fibrin matrix was used as part of anastomotic technique in conjunction with activated thrombocytes (Obsidian ASG®). During anastomosis, this matrix was applied after resection onto the colorectal tissue surfaces with the aim of triggering tissue regeneration and improved wound healing.

Conditions

Interventions

TypeNameDescription
PROCEDUREObsidian ASG®As part of the elective laparoscopic colorectal surgery, an autologous fibrin matrix was used as part of anastomotic technique in conjunction with activated thrombocytes (Obsidian ASG®). During anastomosis, this matrix was applied after resection onto the colorectal tissue surfaces with the aim of triggering tissue regeneration and improved wound healing.

Timeline

Start date
2018-06-01
Primary completion
2021-03-31
Completion
2021-12-31
First posted
2020-05-13
Last updated
2023-10-05

Locations

1 site across 1 country: Austria

Source: ClinicalTrials.gov record NCT04386148. Inclusion in this directory is not an endorsement.